Anne M Filppula

List of Publications by Year
in descending order

20	980	567281 15	752698 20
papers	citations	h-index	g-index

20	20	20	1293
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Translational aspects of cytochrome P450â€mediated drugâ€“drug interactions: A case study with clopidogrel. Basic and Clinical Pharmacology and Toxicology, 2022, 130, 48-59.	2.5	3
2	Comparative Hepatic and Intestinal Metabolism and Pharmacodynamics of Statins. Drug Metabolism and Disposition, 2021, 49, 658-667.	3.3	19
3	Comparative Hepatic and Intestinal Efflux Transport of Statins. Drug Metabolism and Disposition, 2021, 49, 750-759.	3.3	31
4	An automated cocktail method for in vitro assessment of direct and time-dependent inhibition of nine major cytochrome P450 enzymes â€“ application to establishing CYP2C8 inhibitor selectivity. European Journal of Pharmaceutical Sciences, 2021, 162, 105810.	4.0	7
5	Clinical Studies on Drugâ€“Drug Interactions Involving Metabolism and Transport: Methodology, Pitfalls, and Interpretation. Clinical Pharmacology and Therapeutics, 2019, 105, 1345-1361.	4.7	107
6	Improved predictions of time-dependent drug-drug interactions by determination of cytosolic drug concentrations. Scientific Reports, 2019, 9, 5850.	3.3	15
7	Critical Differences between Enzyme Sources in Sensitivity to Detect Time-Dependent Inactivation of CYP2C8. Drug Metabolism and Disposition, 2019, 47, 436-443.	3.3	7
8	Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8â€Mediated Metabolism of Montelukast in Humans. Clinical Pharmacology and Therapeutics, 2018, 104, 495-504.	4.7	14
9	Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions^{â€‰}. Drug Metabolism and Disposition, 2018, 46, 141-150.	3.3	22
10	In Vitro Screening of Six Protein Kinase Inhibitors for Timeâ€Dependent Inhibition of CYP2C8 and CYP3A4: Possible Implications with regard to Drugâ€“Drug Interactions. Basic and Clinical Pharmacology and Toxicology, 2018, 123, 739-748.	2.5	14
11	Validation and development of MTH1 inhibitors for treatment of cancer. Annals of Oncology, 2016, 27, 2275-2283.	1.2	111
12	Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60â€yearâ€old Caucasian woman with ovarian carcinoma. British Journal of Clinical Pharmacology, 2016, 81, 313-315.	2.4	20
13	Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. Pharmacological Reviews, 2016, 68, 168-241.	16.0	175
14	Glucuronidation Converts Clopidogrel to a Strong Time-Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drugâ€“Drug Interactions. Clinical Pharmacology and Therapeutics, 2014, 96, 498-507.	4.7	124
15	In Vitro Assessment of Time-Dependent Inhibitory Effects on CYP2C8 and CYP3A Activity by Fourteen Protein Kinase Inhibitors. Drug Metabolism and Disposition, 2014, 42, 1202-1209.	3.3	56
16	Autoinhibition of CYP3A4 Leads to Important Role of CYP2C8 in Imatinib Metabolism: Variability in CYP2C8 Activity May Alter Plasma Concentrations and Response. Drug Metabolism and Disposition, 2013, 41, 50-59.	3.3	57
17	Gemfibrozil Impairs Imatinib Absorption and Inhibits the CYP2C8-Mediated Formation of Its Main Metabolite. Clinical Pharmacology and Therapeutics, 2013, 94, 383-393.	4.7	28
18	Potent mechanismâ€based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. British Journal of Pharmacology, 2012, 165, 2787-2798.	5.4	74

#	Article	IF	Citations
19	Reevaluation of the Microsomal Metabolism of Montelukast: Major Contribution by CYP2C8 at Clinically Relevant Concentrations. Drug Metabolism and Disposition, 2011, 39, 904-911.	3.3	42
20	Gemfibrozil Markedly Increases the Plasma Concentrations of Montelukast: A Previously Unrecognized Role for CYP2C8 in the Metabolism of Montelukast. Clinical Pharmacology and Therapeutics, 2010, 88, 223-230.	4.7	54